Astellas Sees Turnaround With Urology, Transplantation And Oncology Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Fresh off a long-fought bid for OSI, Astellas has rolled out a five-year management plan to bounce back from patent expires and declining sales.